Shield Therapeutics PLC Investor presentation

TIDMSTX

Shield Therapeutics PLC

15 January 2021

Shield Therapeutics plc

("Shield" or the "Group" or the "Company")

Investor presentation

London, UK, 15 January 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru(R)/Accrufer(R) (ferric maltol), announces it will present at the Shares and AJ Bell Investor Evening Webinar, providing an overview of the business and progress being made by the Company.

Tim Watts, Chief Executive Officer, will present online at the Shares Spotlight webinar on Wednesday 20 January 2021. The event starts at 18.00 and Tim will be presenting at 18.55. Investors can register to attend here: https://bit.ly/3sjqqiI

No new material information will be disclosed at the event and the presentation will be made available on the Company website shortly after the events here: https://www.shieldtherapeutics.com/investors/presentations .

For further information please contact:

 
 Shield Therapeutics plc                              www.shieldtherapeutics.com 
 Tim Watts, CEO                                              +44 (0)20 7186 8500 
 Lucy Huntington-Bailey, Company 
  Secretary and General Counsel                              +44 (0)19 1511 8500 
 
   Nominated Adviser and Joint 
   Broker 
 Peel Hunt LLP 
 James Steel/Dr Christopher 
  Golden                                                     +44 (0)20 7418 8900 
 
   Joint Broker 
   finnCap Ltd 
   Geoff Nash/Matt Radley/Alice 
   Lane                                                      +44 (0)20 7220 0500 
 
  Financial PR & IR Advisor 
 Walbrook PR                        +44 (0)20 7933 8780 or shield@walbrookpr.com 
                                           +44 (0)7980 541 893 / +44 (0)7584 391 
 Paul McManus/Lianne Cawthorne                                               303

About Shield Therapeutics plc

Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru(R)/Accrufer(R), a novel, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru(R)/Accrufer(R) has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru(R) is commercialised in the UK and European Union by Norgine B.V. and the Company is currently in the process of evaluating commercialisation options for the US market, including the potential launch of Accrufer (R) in the US by Shield. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.

For more information, please visit www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABAMLTMTIBMRB

(END) Dow Jones Newswires

January 15, 2021 05:00 ET (10:00 GMT)

Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Jun 2024 to Jul 2024